Clinical Advances in

Treating Across the Spectrum of Heart Failure

CME Activities

HF Activities

Translating Clinical Evidence Into Practice at Heart Failure Centers of Excellence: Getting to the Heart of the Matter

Medscape Education, September 2022

Are you up to date with data, guidelines and best practices for patients with heart failure (HF) across the ejection fraction spectrum?

0.50 CPD
Development of Heart Failure Following Myocardial Infarction: What Is the Unmet Need?

Medscape Education, June 2023

Do you know how to manage and monitor a patient at risk of or with heart failure (HF) post-myocardial infarction (MI)?

0.25 CME
Development of Heart Failure Following Myocardial Infarction: Why Risks Still Remain High

Medscape Education, June 2023

Did you know that 1 in 5 patients develop heart failure within 5 years following myocardial infarction?

0.25 CME
Que savez-vous des inhibiteurs de SGLT2, de l’insuffisance cardiaque, des nouvelles recommandations et de leur mise en œuvre ?

Medscape Education, May 2023

Saviez-vous que certains traitements de l’insuffisance cardiaque (IC) peuvent améliorer le pronostic de l’IC sur tout le spectre de la fraction d’éjection ?
What Do You Know About SGLT2 Inhibitors, Heart Failure, New Guidelines, and Implementation?

Medscape Education, May 2023

Did you know that some heart failure (HF) agents can improve HF outcomes across the spectrum of ejection fraction?

0.50 CME
¿Qué sabe acerca de los inhibidores del cotransportador de sodio y glucosa de tipo 2, la insuficiencia cardíaca, las nuevas guías y su implementación?

Medscape Education, May 2023

¿Sabía que algunos fármacos para la insuficiencia cardíaca pueden mejorar los resultados en todo el espectro de la fracción de eyección?
Was wissen Sie über SGLT2-Inhibitoren, Herzinsuffizienz, neue Leitlinien und deren Umsetzung?

Medscape Education, May 2023

Wussten Sie, dass einige Mittel zur Behandlung der Herzinsuffizienz (Heart Failure, HF) die Ergebnisse der HF über das gesamte Spektrum der Auswurffraktion hinweg verbessern können?

Spectrum of Heart Failure

Heart Failure Treatment: Test Your Knowledge

Resources

Downloadable Slide Kit

Clinical Advances in Treating Across the Spectrum of Heart Failure

Clinical Reference

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction
2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee

Steering Committee

Biykem Bozkurt, MD, PhD

Professor of Medicine-Cardiology
Baylor College of Medicine
Houston, Texas, USA

Andrew JS Coats, DM, DSc, MBA

Professor
Monash University
Melbourne, Australia
University of Warwick
Coventry, Warwickshire, United Kingdom

Carolyn S.P. Lam, MBBS, PhD, FRCP, FAMS, FESC, FACC

Professor
Duke-National University of Singapore
Senior Consultant Cardiologist
National Heart Centre Singapore
Singapore, Singapore

Lars Lund, MD, PhD

Professor of Cardiology
Karolinska University Hospital
Stockholm, Sweden

John McMurray, MD, FRCP, FESC, FACC, FAHA

Professor of Medical Cardiology
British Heart Foundation Cardiovascular Research Center
Deputy Clinical Director
Institute of Cardiovascular and Medical Science
University of Glasgow
Glasgow, Scotland, United Kingdom

Shelley Zieroth, MD

Professor, College of Medicine
University of Manitoba
Director, Heart Failure and Heart Transplant Clinics
Head, Medical Heart Failure Program
Winnipeg Regional Health Authority, Cardiac Sciences Program
Winnipeg, Canada

Steering Committee

Biykem Bozkurt, MD, PhD

Steering Committee Member

Has disclosed the following relevant financial relationships

Served as an advisor or consultant for: Amgen; AstraZeneca; Baxter Healthcare Corporation; Bristol Myers Squibb; Relypsa; Sanofi-Aventis; scPharmaceuticals; Vifor Pharma

Received grants for clinical research from: Clinical Event Committee for GUIDE HF Trial sponsored by Abbott Vascular, Data Safety Monitoring Committee of ANTHEM trial (Autonomic Regulation Therapy to Enhance Myocardial Function and Reduce Progression of Heart Failure With Reduced Ejection Fraction) sponsored by Liva Nova

Andrew JS Coats, DM, DSc, MBA

Steering Committee Member

Has disclosed the following relevant financial relationships

Served as an advisor or consultant for: Abbott; Actimed; Arena; AstraZeneca; Boehringer Ingelheim; Cardiac Dimensions; Corvia; CVRx; Enopace; Impulse Dynamics; Menarini; Novartis; Respicardia; Servier; Viatris; Vifor

Carolyn S.P. Lam, MBBS, PhD, FRCP, FAMS, FESC, FACC

Steering Committee Member

Has disclosed the following relevant financial relationships

Served as an advisor or consultant for: Abbott; Actelion; Alleviant Medical; Allysta Pharma; Amgen; AnaCardio AB; Applied Therapeutics; AstraZeneca; Bayer; Boehringer Ingelheim; Boston Scientific; Cytokinetics; Darma Inc.; EchoNous Inc.; Impulse Dynamics; Ionis Pharmaceutical; Janssen Research & Development LLC; Merck; Novartis; Novo Nordisk; Prosciento Inc.; Radcliffe Group Ltd.; Roche Diagnostics; Sanofi; Siemens Healthcare Diagnostics; Us2.ai

Received grants for clinical research from: Bayer; Roche Diagnostics

Patent beneficiary of: Us2.ai

Stock options from: Us2.ai

Owns stock (privately owned) in: Us2.ai

Other: Co-founder and Non-executive Director of Us2.ai

Lars Lund, MD, PhD

Steering Committee Member

Has disclosed the following relevant financial relationships

Served as an advisor or consultant for: AstraZeneca; Bayer; Lexicon; Merck/Merck Sharp & Dohme; Myokardia; Novartis; Pharmacosmos; Respicardia; Vifor Pharma

Served as a speaker or a member of a speakers bureau for: Abbott; AstraZeneca; Bayer; Novartis; Orion Pharma; Vifor Pharma

Received grants for clinical research from: AstraZeneca; Boehringer Ingelheim; Boston Scientific; Novartis; Pharmacosmos; Relypsa; Vifor Pharma

Owns stock, stock options, or bonds from: AnaCardio

Ownership interest: AnaCardio

John McMurray, MD, FRCP, FESC, FACC, FAHA

Steering Committee Member

Has disclosed the following relevant financial relationships

Served as an advisor or consultant for: Alnylam; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Cardurion; Cytokinetics; Dal-Cor; GlaxoSmithKline; Ionis; KBP Biosciences; Novartis; Pfizer; Theracos

Served as a speaker or a member of a speakers bureau for: Abbott; Alkem Metabolics; Eris Lifesciences; Hikma; Lupin; Servier; Sun Pharmaceuticals; the Corpus

Received grants for clinical research from: Alnylam; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Cardurion; Cytokinetics; Dal-Cor; GlaxoSmithKline; Ionis; KBP Biosciences; Novartis; Pfizer; Theracos

Shelley Zieroth, MD

Steering Committee Member

Has disclosed the following relevant financial relationships:

Served as an advisor or consultant for: Abbott; Akcea; AstraZeneca; Amgen; Alnylam; Bayer; Boehringer Ingelheim; Eli Lilly; Merck; Novartis; Novo Nordisk; Otsuka; Pfizer; Servier; Vifor

Served as a speaker or a member of a speakers bureau for: Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Eli Lilly; HLS Therapeutics; Janssen; Novartis; Servier; Vifor

Received grants for clinical research from: Novartis; Servier

Other: Contractor researcher: Clinical Trials: Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Eidos; Merck; Novartis